Brimonidine Ophthalmic Drops, Solution 0.15pct Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Brimonidine: Ophthalmic drops, solution (0.15%)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png
Brimonidine 0.15% Ophth Soln
Drug Image file default-drug-image.png
Brimonidine 0.15% Ophth Soln
Drug Image file default-drug-image.png
Brimonidine 0.15% Ophth Soln

What is this Medicine?

BRIMONIDINE (bri MOE ni deen) is used to to treat open-angle glaucoma and high pressure in the eye.

CVS Pharmacy Patient Statistics for Brimonidine: Ophthalmic drops, solution(0.15%)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Brimonidine Tartrate 0.15% Ophthalmic Solution

NDC: 613140144
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Glaucoma, Ocular Hypertension

Storage Information
Store between 59 to 77 degrees F
Brimonidine Tartrate 0.15% Ophthalmic Solution

Reported Side Effects for Brimonidine Tartrate 0.15% Ophthalmic Solution

Upset Stomach Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Eye Drainage Incidence:
<4.0%*
Severity: MILD
Onset: DELAYED
Rapid Heart Rate Incidence:
<1.0%*
Severity: MODERATE
Onset: RAPID
Rapid Heart Rate Incidence:
<3.0%*
Severity: MODERATE
Onset: EARLY
Bleeding Within The Eye Incidence:
<4.0%*
Severity: SEVERE
Onset: DELAYED
Dry Nose Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Miosis Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Tiredness Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Low Muscle Tone Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Metallic Taste Incidence:
<4.0%*
Severity: MILD
Onset: EARLY
Decreased Breathing Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Fainting Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Low Body Temperature Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Inflamed Eye Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Inflamed Iris (Eye) Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Nervousness Incidence:
<3.0%*
Severity: MILD
Onset: DELAYED
Slow Heart Beat Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Coma Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Depression Incidence:
<3.0%*
Severity: MODERATE
Onset: DELAYED
Inability To Sleep Incidence:
<4.0%*
Severity: MILD
Onset: EARLY
High Blood Pressure Incidence:
<9.0%*
Severity: MODERATE
Onset: EARLY
Inflamed Eyes Incidence:
1.0-9.0%*
Severity: MODERATE
Onset: EARLY
Low Blood Pressure Incidence:
1.0-4.0%*
Severity: MODERATE
Onset: RAPID
Rhinitis Incidence:
1.0-4.0%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
1.0-4.0%*
Severity: MILD
Onset: EARLY
Eye Inflammatoin Incidence:
1.0-4.0%*
Severity: SEVERE
Onset: DELAYED
Cough Incidence:
1.0-4.0%*
Severity: MILD
Onset: DELAYED
Drowsiness Incidence:
1.0-30.0%*
Severity: MILD
Onset: EARLY
Keratopathy Incidence:
1.0-4.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
1.0-4.0%*
Severity: MILD
Onset: EARLY
Foreign Body Sensation Incidence:
1.0-30.0%*
Severity: MILD
Onset: RAPID
Epiphora Incidence:
1.0-4.0%*
Severity: MODERATE
Onset: EARLY
Shortness Of Breath Incidence:
1.0-4.0%*
Severity: MODERATE
Onset: EARLY
Lightheadedness Incidence:
1.0-9.0%*
Severity: MILD
Onset: EARLY
Conjunctivitis Incidence:
1.0-20.0%*
Severity: MODERATE
Onset: DELAYED
Eye Pain Incidence:
1.0-9.0%*
Severity: MILD
Onset: EARLY
Sore Throat Incidence:
1.0-5.0%*
Severity: MILD
Onset: DELAYED
Light Sensitivity Incidence:
1.0-9.0%*
Severity: MODERATE
Onset: EARLY
Sinus Infection Incidence:
1.0-4.0%*
Severity: MILD
Onset: DELAYED
Dry Eyes Incidence:
1.0-9.0%*
Severity: MILD
Onset: EARLY
Cataracts Incidence:
1.0-4.0%*
Severity: MODERATE
Onset: DELAYED
High Cholesterol Incidence:
1.0-4.0%*
Severity: MODERATE
Onset: DELAYED
Infection Incidence:
1.0-4.0%*
Severity: MILD
Onset: DELAYED
Flu Incidence:
1.0-4.0%*
Severity: MILD
Onset: DELAYED
Decreased Breathing Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: RAPID
Headache Incidence:
1.0-30.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
1.0-30.0%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
1.0-9.0%*
Severity: MILD
Onset: DELAYED
Blurred Vision Incidence:
1.0-30.0%*
Severity: MODERATE
Onset: EARLY
Muscle And/Or Bone Pain Incidence:
3.0-9.0%*
Severity: MILD
Onset: EARLY
Eye Irritation Incidence:
3.0-9.0%*
Severity: MILD
Onset: RAPID
Visual Impairment Incidence:
3.0-9.0%*
Severity: SEVERE
Onset: EARLY
Skin Redness Incidence:
4.0-8.0%*
Severity: MODERATE
Onset: EARLY
Dry Mouth Incidence:
5.0-30.0%*
Severity: MILD
Onset: EARLY
Red Eyes Incidence:
10.0-30.0%*
Severity: MODERATE
Onset: EARLY
Itchy Eyes Incidence:
10.0-30.0%*
Severity: MILD
Onset: RAPID
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Brimonidine Tartrate 0.15% Ophthalmic Solution

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Moderate Lifestyle Interaction
Alcohol and Brimonidine Tartrate 0.15% Ophthalmic Solution(Brimonidine Tartrate)
Alcohol and Brimonidine Tartrate(Brimonidine Tartrate)
Avoid or minimize your intake of Ethanol (alcohol-containing drinks) while taking Brimonidine Eye Solution. You may feel drowsy or more tired; do not drive or operate machinery while taking these products together.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Brimonidine

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.